XTNT — Xtant Medical Holdings Share Price
0.000.00%
Last trade - 00:00- $67.33m
- $67.48m
- $133.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.39 | ||
| Price to Tang. Book | 1.59 | ||
| Price to Free Cashflow | 8.67 | ||
| Price to Sales | 0.55 | ||
| EV to EBITDA | 5.92 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.11% | ||
| Return on Equity | 3.95% | ||
| Operating Margin | 5.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 55.26 | 57.97 | 91.3 | 117.27 | 133.93 | 102.41 | 111.98 | 20.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
Directors
- Jeffrey Peters CHM (53)
- Sean Browne PRE (55)
- Scott Neils CFO
- Kevin Brandt OTH (55)
- Michael Eggenberg DRC (51)
- Matthew Rizzo DRC (48)
- John Bakewell IND (60)
- Robert McNamara IND (64)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- August 8th, 2006
- Public Since
- June 30th, 2010
- No. of Shareholders
- 162
- No. of Employees
- 151
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 140,262,960
- Address
- 664 Cruiser Lane, BELGRADE, 59714
- Web
- https://xtantmedical.com/
- Phone
- +1 4063880480
- Auditors
- Grant Thornton LLP
Upcoming Events for XTNT
Xtant Medical Holdings Inc Annual Shareholders Meeting
Q3 2026 Xtant Medical Holdings Inc Earnings Release
Similar to XTNT
Acme United
NYSE MKT
Alpha Pro Tech
NYSE MKT
Catheter Precision
NYSE MKT
Electromed
NYSE MKT
Infusystem Holdings
NYSE MKT
FAQ
What is the Xtant Medical Holdings share price?
As of Today at 15:12 UTC, shares in Xtant Medical Holdings are trading at $0.48. This share price information is delayed by 15 minutes.
How has the Xtant Medical Holdings share price performed this year?
Shares in Xtant Medical Holdings last closed at $0.48 and the price had moved by -33.93% over the past 365 days. In terms of relative price strength the Xtant Medical Holdings share price has underperformed the S&P500 Index by -48.7% over the past year.
What are the analyst and broker recommendations for Xtant Medical Holdings?
The overall consensus recommendation for Xtant Medical Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Xtant Medical Holdings dividend yield?
Xtant Medical Holdings does not currently pay a dividend.
Does Xtant Medical Holdings pay a dividend?
Xtant Medical Holdings does not currently pay a dividend.
When does Xtant Medical Holdings next pay dividends?
Xtant Medical Holdings does not currently pay a dividend.
How do I buy Xtant Medical Holdings shares?
To buy shares in Xtant Medical Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xtant Medical Holdings?
As of the previous close price of $0.48, shares in Xtant Medical Holdings had a market capitalisation of $67.33m.
Where are Xtant Medical Holdings shares listed?
Here are the trading details for Xtant Medical Holdings:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: XTNT
What kind of share is Xtant Medical Holdings?
Based on an overall assessment of its quality, value and momentum Xtant Medical Holdings is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xtant Medical Holdings share price forecast for 2026?
The analyst consensus target price for shares in Xtant Medical Holdings is $1.23. That is 156.25% above the last closing price of $0.48.
Analysts covering Xtant Medical Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.03 for the next financial year.
Find out moreWhat is the trend in the Xtant Medical Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xtant Medical Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -30.65%.
As of the last closing price of $0.48, shares in Xtant Medical Holdings were trading -24.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xtant Medical Holdings PE Ratio?
The Xtant Medical Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xtant Medical Holdings?
Xtant Medical Holdings' management team is headed by:
- Jeffrey Peters - CHM
- Sean Browne - PRE
- Scott Neils - CFO
- Kevin Brandt - OTH
- Michael Eggenberg - DRC
- Matthew Rizzo - DRC
- John Bakewell - IND
- Robert McNamara - IND